Invention Grant
- Patent Title: Anti-CCR7 antibody drug conjugates
-
Application No.: US16482173Application Date: 2018-02-01
-
Publication No.: US11634497B2Publication Date: 2023-04-25
- Inventor: Steven Bender , Tracy Charlton , Anna Galkin , Bernhard Hubert Geierstanger , Scott Martin Glaser , Shailaja Kasibhatla , Mark Knuth , Sabine Rottmann , Sarah Rue , Glen Spraggon , Tetsuo Uno
- Applicant: NOVARTIS AG
- Applicant Address: CH Basel
- Assignee: NOVARTIS AG
- Current Assignee: NOVARTIS AG
- Current Assignee Address: CH Basel
- Agent Elizabeth T. Karnas
- International Application: PCT/IB2018/050639 WO 20180201
- International Announcement: WO2018/142322 WO 20180809
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K47/68 ; A61P35/00 ; A61K39/00

Abstract:
This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
Public/Granted literature
- US20200216548A1 ANTI-CCR7 ANTIBODY DRUG CONJUGATES Public/Granted day:2020-07-09
Information query